CorMedix outlines $300M–$320M revenue and $100M–$125M EBITDA targets for 2026 amid DefenCath transition and Melinta integration

Earnings Call Insights: CorMedix Inc. (CRMD) Q4 2025

MANAGEMENT VIEW

* CEO Joseph Todisco stated that “2025 was truly a transformational year for CorMedix. While DefenCath achieved peak sales of just under $260 million, we are excited to have both announced and closed the acquisition of Melinta Therapeutics in the third quarter of the year. In addition, the team worked expeditiously to facilitate integration and achieve our target synergy of $35 million during the fourth quarter of 2025.”
* Todisco affirmed guidance for 2026 DefenCath revenue of $150 million to $170 million and 2027 DefenCath revenue of $100 million to $125 million. He emphasized, “We are also affirming its full year 2026 financial guidance of revenue of $300 million to $320 million and adjusted EBITDA of $100 million to $125 million.”
* The CEO discussed the transition of DefenCath’s reimbursement from TDAPA to a bundled add-on mechanism, with supply pricing for Q3, Q4 2026, and 2027 being finalized, and highlighted ongoing discussions with Medicare Advantage providers and new customers.
* Todisco described the first Analyst R&D Day focused on the antifungal product REZZAYO and pipeline developments, noting, “The feedback from thought leaders was excellent and underscores our view for the large potential market opportunity for REZZAYO, which we estimate at approximately $2.5 billion across both potential indications and for DefenCath and TPN, which we estimate between $500 million and $750 million.”
* EVP & Chief Operating Officer Elizabeth Masson-Hurlburt reported, “The global Phase III ReSPECT study evaluating REZZAYO for the prophylaxis of fungal infections in adult allogeneic bone marrow transplant patients completed in September,” with top line data expected in Q2 2026.
* EVP & Chief Financial Officer Susan Blum stated, “For the fourth quarter, net revenue of $128.6 million reflected continued growth across our commercial portfolio, driven primarily by DefenCath, which contributed $91.2 million and supplemented by a full quarter contribution from the Melinta portfolio, which totaled $37.4 million.” Blum also said, “Adjusted EBITDA for the fourth quarter was $77.2 million, which was within our previously established guidance and reflects modest growth quarter-over-quarter.”

OUTLOOK

* The company is affirming 2026 DefenCath guidance of $150 million to $170 million, 2027 DefenCath guidance of $100 million to $125 million, and full year 2026 financial guidance of revenue of $300 million to $320 million and adjusted EBITDA of $100 million to $125 million.
* Management expects “much of the revenue concentration to be front-loaded in the first half of the year as price erosion related to the post-TDAPA add-on occurs in the third and fourth quarter.”
* Todisco indicated the 2027 bundle adjustment could result in “a higher net selling price in 2027 compared to Q3 and Q4 of 2026.”

FINANCIAL RESULTS

* Blum detailed, “Net revenue of $128.6 million reflected continued growth across our commercial portfolio, driven primarily by DefenCath, which contributed $91.2 million and supplemented by a full quarter contribution from the Melinta portfolio, which totaled $37.4 million compared to net revenue of $31.2 million in the fourth quarter of 2024.”
* Operating expenses for the fourth quarter were $48.2 million, up from $17.1 million in the prior year, due to expanded cost structure and merger-related costs.
* The company reported net income of $14 million for the fourth quarter of 2025, with pretax income of $56.4 million.
* Cash and cash equivalents and short-term investments ended the quarter at $148.5 million, “driven by strong operating cash flow of almost $100 million during the quarter.”

Q&A

* Roanna Clarissa Ruiz, Leerink Partners LLC, asked about contract pricing for DefenCath and volume drivers for 2026 and beyond. Todisco responded, “The near-term focus is on preserving patient utilization through the back part of '26 and creating a structure for an increase in selling price in '27… We are also setting these up with flexibility to allow for changes in the event we are successful with Medicare Advantage contracting as we progress through this year and into next year.”
* Ruiz followed up on the REZZAYO Phase III data, and Todisco emphasized the importance of “various degrees of success,” while Masson-Hurlburt added that data-dependent outcomes will inform payer and clinical strategy, especially highlighting the lack of drug-drug interactions compared to Azoles.
* An analyst (Jean for Les Sulewski, Truist Securities) asked about TDAPA extension bills and LDO partnerships. Todisco said, “The legislation is always speculative… timing is tricky… There’s a war in the Middle East. So we really can’t speculate on whether this can happen before June 30 or December 31.”
* John for Serge Belanger, Needham & Company, asked about DefenCath’s inpatient opportunity and the Melinta portfolio. Todisco said the 2026 guidance is based on floor pricing and that upside from Medicare Advantage or new customers is not included in 2027 guidance. MINOCIN and VABOMERE were described as durable, with a few percentage points of growth expected.
* Brandon Folkes, H.C. Wainwright, inquired about customer mix for DefenCath and anticipated changes. Todisco noted, “We’re fairly heavily concentrated volume-wise with one of the LDOs and then 2 of the 3 midsized players are driving probably 90-something percent of our volume amongst the 3 of them.”
* Folkes also asked about operating cash flow, with Todisco saying EBITDA is a proxy, but noted impacts from inventory and rebates.

SENTIMENT ANALYSIS

* Analysts focused on details regarding DefenCath pricing, volume preservation, and guidance structure, reflecting a neutral to slightly cautious tone, with questions probing reimbursement risk and product adoption sustainability.
* Management’s sentiment was confident during prepared remarks, using phrases like “we are excited,” “we remain confident,” and “we are hopeful,” but displayed caution in Q&A, particularly around legislative issues and reimbursement, as seen in Todisco’s statement about TDAPA extension timing being “always speculative.”
* Compared to the previous quarter, analysts’ tone remained focused on reimbursement and growth sustainability, while management shifted from a highly optimistic tone post-acquisition to a more measured stance, balancing confidence in guidance with acknowledgment of external uncertainties.

QUARTER-OVER-QUARTER COMPARISON

* Guidance for 2026 and 2027 DefenCath revenue was reaffirmed, while full year 2026 revenue and adjusted EBITDA targets were issued for the first time at specific ranges.
* Strategic focus shifted to managing the DefenCath transition from TDAPA to bundled reimbursement and integrating the Melinta acquisition.
* Management’s tone moved from celebratory and acquisition-focused to execution and mitigation of reimbursement transition risks.
* Analysts’ focus evolved from post-acquisition integration and pipeline catalysts in Q3 to pricing, volume, and reimbursement risk for DefenCath in Q4.
* Key metric changes included a full quarter of Melinta revenue now contributing to results, and strong operating cash flow positioning for further growth initiatives.

RISKS AND CONCERNS

* Management flagged price erosion for DefenCath in the second half of 2026 as a key challenge and emphasized efforts to “preserve patient utilization through the back part of '26 and creating a structure for an increase in selling price in '27.”
* Legislative timing for TDAPA extension bills was described as uncertain and outside management’s control.
* Guidance does not include upside from potential Medicare Advantage contracts or new customers, reflecting a conservative approach to 2027 projections.
* Analysts repeatedly questioned the sustainability of DefenCath’s pricing and customer mix, as well as the impact from potential legislative or reimbursement changes.

FINAL TAKEAWAY

CorMedix management emphasized that 2025 was a year of transformation with the Melinta acquisition and record DefenCath sales, while 2026 is expected to be a transitional year marked by reimbursement changes and integration execution. The company reaffirmed robust financial guidance, highlighted a strong cash position, and pointed to clinical and commercial catalysts ahead, particularly the upcoming Phase III REZZAYO data and ongoing expansion opportunities for DefenCath. Management underscored its confidence in maintaining growth and profitability, supported by operational execution, diversified portfolio, and prudent financial planning.

Read the full Earnings Call Transcript [https://seekingalpha.com/symbol/crmd/earnings/transcripts]

MORE ON CORMEDIX

* CorMedix Inc. (CRMD) Q4 2025 Earnings Call Transcript [https://seekingalpha.com/article/4879132-cormedix-inc-crmd-q4-2025-earnings-call-transcript]
* CorMedix Inc. (CRMD) Analyst/Investor Day Transcript [https://seekingalpha.com/article/4868358-cormedix-inc-crmd-analyst-investor-day-transcript]
* CorMedix Inc. (CRMD) Analyst/Investor Day - Slideshow [https://seekingalpha.com/article/4868762-cormedix-inc-crmd-analyst-investor-day-slideshow]
* CorMedix nears an 11-month low after earnings miss [https://seekingalpha.com/news/4561353-cormedix-stock-falls-earnings-miss]
* CorMedix reports mixed Q4 results; reaffirms FY26 outlook [https://seekingalpha.com/news/4561233-cormedix-reports-mixed-q4-results-reaffirms-fy26-outlook]